Plan B Delay Draws Criticism From Congress, Academia, FDA Official
Executive Summary
FDA's handling of Barr's application to switch Plan B over the counter could elicit heightened external scrutiny of the agency's ability to make drug approval decisions based solely on science and public health
You may also be interested in...
Plan C? The Plan B Decision and Calls for a Third Class of Drugs
HHS Secretary Sebelius’ decision to overturn FDA’s approval of Plan B for widespread over-the-counter use was disappointing to many drug reviewers inside the agency. But FDA’s Office of New Drugs Director John Jenkins says the move should be used to reopen the debate over whether to create a third class of drugs. And Plan B, he says, might be a perfect place to start.
Plan C? The Plan B Decision and Calls for a Third Class of Drugs
HHS Secretary Sebelius’ decision to overturn FDA’s approval of Plan B for widespread over-the-counter use was disappointing to many drug reviewers inside the agency. But FDA’s Office of New Drugs Director John Jenkins says the move should be used to reopen the debate over whether to create a third class of drugs. And Plan B, he says, might be a perfect place to start.
Galson Backed Initial Plan B Denial In Fear His Job Was In Jeopardy – Jenkins
Center for Drug Evaluation & Research Director Steven Galson initially signed off on the "not approvable" letter for Barr's emergency contraceptive Plan B OTC switch in fear that he would lose his job, according to testimony by senior CDER officials